How do MS clinic nurses explain disease-modifying therapy to Spanish-speaking patients who stopped their medication because they felt cured?

The most common DMT adherence failure in MS nursing — across every language — is the patient who stops her medication because she feels well, having concluded that feeling well means the disease is gone. This is not a failure of intelligence; it is a logical inference from how most other medications work. You take an antibiotic until the infection clears and then you stop. You take ibuprofen until the pain is gone and then you stop. The gap is that disease-modifying therapies for MS do not work the way those medications work. They do not treat a current episode. They do not clear an infection. They do not fix the damage from past relapses. What they do is suppress the inflammatory mechanism that the immune system uses to attack the myelin sheath — and they do that continuously, not episodically. A patient on interferon beta-1a who has had no relapses in eighteen months has no relapses partly because the medication is suppressing the inflammatory cascade that would otherwise produce them. Stopping the medication does not lock in the remission. It removes the suppression. The immune system is still capable of launching new attacks; the medication was what was preventing that from happening. The MS clinic nurse who explains this mechanism — not as a correction but as information the patient needed but did not have — is the person who prevents the relapse that follows a medication stop. “El medicamento no curó la EM — lo que hizo fue suprimir el mecanismo con el que el sistema inmune ataca la mielina. Mientras el medicamento está activo en su cuerpo, ese mecanismo está frenado. Cuando se para el medicamento, el freno se quita. La EM no desapareció — se quedó tranquila porque el medicamento no la dejaba actuar. Sentirse bien es exactamente la señal de que el medicamento estaba funcionando.” (The medication did not cure the MS — what it did was suppress the mechanism the immune system uses to attack myelin. While the medication is active in your body, that mechanism is braked. When the medication stops, the brake is removed. The MS did not disappear — it was quiet because the medication was not letting it act. Feeling well is exactly the signal that the medication was working.)

How do MS clinic nurses explain MRI lesions to Spanish-speaking patients whose relapses resolved but whose imaging shows new activity?

The disconnect between subjective experience and MRI findings is one of the most important and least understood aspects of MS for patients. A relapse is a neurological event with symptoms the patient can feel: visual disturbance, limb weakness, balance problems, sensory loss. When the relapse resolves — as most relapses do, partially or fully — the patient experiences the resolution as recovery, and often concludes that the disease is no longer active. What the MRI can show, and what the clinical exam cannot always detect, is that the disease process continued producing new lesions between the relapse the patient felt and the scan that was ordered. These silent lesions are areas of demyelination where the location of the injury happened to spare the pathways that produce noticeable symptoms — but the inflammatory damage was real, the axons at risk are real, and the cumulative lesion burden over time is the primary driver of long-term disability in relapsing MS. The MS clinic nurse who explains the relationship between what the patient felt and what the MRI shows — why the resolution of a symptom does not mean the disease stopped and why new lesions that produce no symptoms are still clinically significant — is the person who makes the case for treatment escalation comprehensible. “La resonancia muestra la actividad de la EM en todo el cerebro, no solo en las áreas que producen síntomas que usted puede sentir. Las tres lesiones nuevas están en zonas donde la EM estuvo activa durante estos meses — pero el daño quedó en partes del cerebro que no producen síntomas visibles en este momento. El hecho de que no los haya sentido no significa que no estuvieran pasando.” (The MRI shows MS activity across the entire brain, not only in the areas that produce symptoms you can feel. The three new lesions are in areas where MS was active during these months — but the damage landed in parts of the brain that do not produce visible symptoms right now. The fact that you did not feel them does not mean they were not happening.)

How do MS clinic nurses explain the difference between relapsing-remitting MS and primary progressive MS to Spanish-speaking patients?

Most patients know the name of their MS diagnosis but do not understand what the subtype means for their disease course or for their treatment options. Relapsing-remitting MS (RRMS) is characterized by discrete attacks — clinically defined relapses — followed by partial or full recovery. The biological mechanism of a relapse is acute inflammation: the immune system launches an inflammatory attack on the myelin sheath, producing the lesion that causes the symptom. Disease-modifying therapies approved for RRMS target this inflammatory mechanism. They reduce the frequency and severity of those inflammatory attacks. Primary progressive MS (PPMS) has a fundamentally different course: instead of discrete attacks and recoveries, neurological function declines gradually and continuously from onset, without clear relapses. The biological mechanism of PPMS is dominated by progressive neurodegeneration and axon loss — not by the acute inflammatory lesion-forming process that drives RRMS relapses. Because most DMTs approved before 2017 targeted the relapse mechanism, they showed little benefit in PPMS trials. Ocrelizumab, approved in 2017, is the only FDA-approved treatment for PPMS; it targets B cells rather than purely the relapse cascade, and trials showed modest slowing of disability progression — not stopping, not reversing, but slowing. “La diferencia entre los dos tipos no es cuánto afecta — es el mecanismo. La EM recidivante-remitente tiene brotes: el sistema inmune ataca la mielina, produce síntomas, y después se calma. Los medicamentos que aparecen en los anuncios están diseñados para frenar esos brotes. La EM primaria progresiva no tiene brotes — progresa gradualmente desde el principio por un mecanismo diferente. El medicamento que existe para la EM primaria progresiva es el ocrelizumab, que actuar sobre un componente del sistema inmune diferente y que en los ensayos clínicos mostró una desaceleración modesta de la progresión. No son los mismos medicamentos porque no son el mismo proceso.” (The difference between the two types is not how much it affects — it is the mechanism. Relapsing-remitting MS has relapses: the immune system attacks myelin, produces symptoms, and then quiets down. The medications in the advertisements are designed to suppress those relapses. Primary progressive MS does not have relapses — it progresses gradually from the start through a different mechanism. The medication that exists for primary progressive MS is ocrelizumab, which acts on a different component of the immune system and which in clinical trials showed modest slowing of progression. They are not the same medications because they are not the same process.)

What should MS clinic nurses say in Spanish when a patient asks whether stopping her disease-modifying therapy will cause a relapse?

This is one of the most important questions in MS clinic nursing, and the honest answer is that stopping a DMT increases the risk of relapse, but the timing, severity, and whether a relapse occurs at all cannot be predicted for a specific patient. What the data show is a pattern: across clinical trials and real-world registries, patients who discontinue effective DMTs have a higher rate of relapse activity in the following months than patients who continue. The most clinically significant risk is not from an ordinary stop but from an abrupt discontinuation after a highly effective agent — particularly natalizumab (Tysabri) — where rebound inflammatory activity has been documented in some patients, sometimes producing severe multifocal relapses. For a patient stopping a first-line injectable like interferon beta-1a, the risk is real but the rebound phenomenon is not the same. What the MS clinic nurse can say honestly is: we cannot promise a relapse will happen, and we cannot promise one will not. What we know is that the medication was preventing the immune system from attacking your myelin. The attack risk returns when the medication stops. “No podemos decirle con certeza si va a tener un brote ahora que paró el medicamento — ni cuándo. Lo que sí podemos decir es que el medicamento estaba frenando al sistema inmune de atacar la mielina. Ese freno ya no está. La EM no desapareció cuando se sintió mejor — el medicamento simplemente la mantenía quieta. Lo que queremos hacer ahora es retomarlo lo antes posible para volver a tener esa protección.” (We cannot tell you with certainty whether you will have a relapse now that you stopped the medication — or when. What we can say is that the medication was braking the immune system from attacking myelin. That brake is no longer there. The MS did not disappear when you felt better — the medication was simply keeping it quiet. What we want to do now is resume it as soon as possible to have that protection again.)

What are the most important Spanish phrases for multiple sclerosis clinic nurses working with Spanish-speaking MS patients?

MS clinic nursing involves three recurring communication failures that are specific to this disease: the patient who stops her disease-modifying therapy because feeling well feels like a cure (the most common adherence failure in MS); the patient whose relapse resolved and who cannot understand why MRI is still showing new activity or why the neurologist is recommending a change in treatment; and the patient with primary progressive MS who does not understand why the medications she sees advertised for MS are not available to her. In each case the nurse who explains the mechanism — how DMTs work, why MRI findings diverge from subjective experience, why PPMS and RRMS are different diseases at the biological level — prevents the most consequential errors: a preventable relapse, a delayed escalation while silent lesions accumulate, and a patient who disengages from a clinic she concludes cannot help her. For DMT adherence: “sentirse bien es la señal de que el medicamento estaba funcionando — no de que la EM se curó.” For silent MRI lesions: “la resonancia puede mostrar actividad de la EM en lugares donde el daño no produce síntomas que usted pueda sentir — pero el daño está ahí y acumula.” For PPMS: “los medicamentos de los anuncios están diseñados para frenar los brotes de la EM recidivante — un proceso diferente del que tiene usted. El tratamiento para la EM primaria progresiva existe y es diferente.” (For DMT adherence: “feeling well is the signal that the medication was working — not that the MS was cured.” For silent MRI lesions: “the MRI can show MS activity in places where the damage does not produce symptoms you can feel — but the damage is there and accumulates.” For PPMS: “the medications in the advertisements are designed to brake the relapses of relapsing MS — a different process from what you have. Treatment for primary progressive MS exists and is different.”)

July 18, 2026 · Clinical Spanish · Multiple Sclerosis · Neurology Clinic · Chronic Disease Nursing

Spanish for multiple sclerosis clinic nurses — the patient who stopped her disease-modifying injections because she felt fine and concluded the MS must have been cured, the patient whose optic neuritis resolved completely and who cannot understand why his MRI now shows new lesions and his neurologist is recommending a stronger medication, and the patient with primary progressive MS who saw advertisements for the medication that stops MS and does not understand why she is not a candidate

Valentina Torres is 38. She is a hotel housekeeper from Chicago. Twenty months ago she was diagnosed with relapsing-remitting multiple sclerosis after a six-week episode of left leg weakness and fatigue that did not fully resolve. Her neurologist started her on interferon beta-1a injections — three times a week, subcutaneous. The first months were rough. The injection site reactions. The flu-like symptoms the morning after each dose. She pushed through. By month six, she felt better than she had in years.

Three months ago she stopped the injections.

She tells the MS clinic nurse today that she stopped because she felt fine. She had been feeling fine for over a year. She concluded that the medication must have cured whatever the MS was doing, because why else would she feel this good? She did not tell her neurologist. She has been meaning to call the clinic, but she felt fine, so she did not think it was urgent.

— Si me siento bien, quiere decir que ya se curó, ¿verdad? ¿Para qué seguir poniéndome las inyecciones si ya no lo necesito?

If I feel fine, that means it is cured, right? What is the point of continuing the injections if I no longer need them?

What this post covers

This post covers three conversations that recur in multiple sclerosis clinic nursing when the patient speaks Spanish. The first is Valentina’s — the patient who stopped her disease-modifying therapy because remission felt like a cure, who reasoned that a medication you no longer need is a medication you can stop, and who does not yet understand that the absence of symptoms in MS is not evidence that the disease has stopped. The second is Eduardo Sánchez, 44, a restaurant manager from Houston who had optic neuritis fourteen months ago — partial loss of vision in his left eye that frightened him but resolved over six weeks. He was relieved when it resolved and concluded he was therefore fine. His follow-up MRI three weeks ago showed three new lesions, all silent, meaning the MS produced three new areas of demyelination that caused no symptoms he could feel. His neurologist is now recommending escalation to a higher-efficacy treatment, and Eduardo cannot understand why: if he is feeling fine and his only relapse resolved on its own, why does he need stronger medication? The third is María Luisa Reyes, 61, a retired seamstress from San Antonio diagnosed eight months ago with primary progressive MS. She has been watching television and reading online. She has seen advertisements for natalizumab and ocrelizumab described as medications that can change the course of MS. She asked her neurologist at the last appointment why she is not on those medications. She was told she is not a candidate. She did not understand why, and she has spent the past two months concluding on her own either that her MS is too severe to treat or that the medications are being withheld because of her age.

Each of these three patients arrived at the MS clinic with a clinically necessary next step that they cannot accept because the mechanism has not been explained. Valentina cannot resume a medication she believes cured her condition. Eduardo cannot consent to a treatment escalation that seems unnecessary given that he feels fine. María Luisa is disengaging from a clinic she believes cannot help her because it has not given her the medication she has seen advertised. The MS clinic nurse who explains how disease-modifying therapies actually work, why MRI findings diverge from subjective experience, and why primary progressive MS is a biologically different disease from the relapsing form is the person who makes the clinical plan possible.

Scenario one: Valentina and the injections she stopped because she felt cured

MS clinic nurse Cristina Medina reads the chart before going in. Valentina Torres, 38. Relapsing-remitting MS diagnosed twenty months ago. Single relapse: left leg weakness. Started interferon beta-1a, three times weekly. Last documented injection: three months ago, based on the refill history from the pharmacy benefit manager. No new relapses documented. Today is a routine follow-up, but the missing refill is what Cristina noticed first.

She goes in.

Cristina: — Valentina, qué bueno verla. Antes de empezar con los exámenes, tengo una pregunta sobre el medicamento — veo que no ha pedido un reabastecimiento en los últimos tres meses. ¿Me puede contar qué está pasando con las inyecciones?

Valentina, good to see you. Before we start with the exams, I have a question about the medication — I see you have not requested a refill in the past three months. Can you tell me what is happening with the injections?

Valentina: — Las dejé. Me sentía bien. Me sentía mejor que antes del diagnóstico, para ser honesta. Pensé que ya no las necesitaba — que el medicamento había hecho su trabajo y que ya se había curado.

I stopped them. I was feeling well. I was feeling better than before the diagnosis, to be honest. I thought I no longer needed them — that the medication had done its job and the MS had been cured.

Cristina: — Entiendo completamente por qué lo pensó así. Si una infección mejora, para el antibiótico. Si el dolor se va, para el ibuprofeno. La lógica tiene mucho sentido para la mayoría de las enfermedades. Para la esclerosis múltiple, el mecanismo del medicamento es diferente, y eso es algo que necesitamos hablar hoy porque afecta directamente lo que pasa en su cuerpo ahora mismo.

I understand completely why you thought that. If an infection improves, you stop the antibiotic. If the pain goes away, you stop the ibuprofen. The logic makes complete sense for most conditions. For multiple sclerosis, the mechanism of the medication is different, and that is something we need to discuss today because it directly affects what is happening in your body right now.

Valentina: — ¿Qué quiere decir que el mecanismo es diferente?

What do you mean that the mechanism is different?

How disease-modifying therapy works in relapsing-remitting MS

Cristina: — La esclerosis múltiple es una enfermedad del sistema inmune. En la EM, el sistema inmune comete un error — ataca la vaina de mielina que recubre las fibras nerviosas del cerebro y la médula espinal. Cada vez que eso pasa, produce una lesión — un área donde la mielina se daña. Si la lesión está en una zona que controla el movimiento de la pierna, produce debilidad en la pierna. Si está en el nervio óptico, produce problemas visuales. Si está en un área que no controla ninguna función que usted pueda notar, no produce síntomas — pero la lesión sigue ahí.

Multiple sclerosis is a disease of the immune system. In MS, the immune system makes an error — it attacks the myelin sheath that coats the nerve fibers in the brain and spinal cord. Every time that happens, it produces a lesion — an area where the myelin is damaged. If the lesion is in a zone that controls leg movement, it produces leg weakness. If it is in the optic nerve, it produces visual problems. If it is in an area that does not control any function you can notice, it does not produce symptoms — but the lesion is still there.

Valentina: — ¿Pero yo no he tenido más síntomas desde que empecé el medicamento.

But I have not had more symptoms since I started the medication.

Cristina: — Exactamente. Y eso es la clave. El interferón beta-1a no cura la EM. Lo que hace es suprimir parte del mecanismo con el que el sistema inmune ataca la mielina. Reduce la frecuencia con la que el sistema inmune lanza esos ataques. Mientras el medicamento está activo en su cuerpo, ese mecanismo está frenado. Por eso usted no ha tenido brotes en dieciocho meses. No es que la EM se haya curado — es que el medicamento no la dejaba actuar.

Exactly. And that is the key. Interferon beta-1a does not cure MS. What it does is suppress part of the mechanism the immune system uses to attack myelin. It reduces the frequency with which the immune system launches those attacks. While the medication is active in your body, that mechanism is braked. That is why you have not had relapses in eighteen months. It is not that the MS was cured — it is that the medication was not letting it act.

Valentina is quiet. She looks at Cristina.

Valentina: — Entonces cuando lo paré…

So when I stopped it…

Cristina: — Cuando lo paró, el freno desapareció. El sistema inmune de su cuerpo todavía tiene EM. No cambió. Sigue siendo capaz de lanzar ataques contra la mielina. La diferencia es que ahora no tiene el medicamento que lo estaba frenando. Sentirse bien durante dieciocho meses es exactamente la señal de que el medicamento estaba funcionando — no de que podía pararse.

When you stopped it, the brake disappeared. Your body’s immune system still has MS. It did not change. It is still capable of launching attacks against myelin. The difference is that now it does not have the medication that was braking it. Feeling well for eighteen months is exactly the signal that the medication was working — not that it could be stopped.

Valentina: — ¿Y si no lo retomo — qué pasa?

And if I do not resume it — what happens?

What the data show about stopping a disease-modifying therapy

Cristina: — No podemos decirle con certeza que va a tener un brote, ni cuándo. Pero lo que sí sabemos, por estudios en miles de pacientes, es que las personas que paran sus medicamentos de EM tienen más brotes en los meses siguientes que las que los continúan. El riesgo aumenta. No es inevitable — pero es real. Y cada brote que ocurre puede dejar algún daño. A veces el brote se recupera completamente. A veces no. La debilidad de la pierna que tuvo la primera vez — ¿se recuperó al 100%?

We cannot tell you with certainty that you will have a relapse, or when. But what we do know, from studies in thousands of patients, is that people who stop their MS medications have more relapses in the following months than those who continue. The risk increases. It is not inevitable — but it is real. And each relapse that occurs can leave some damage. Sometimes the relapse recovers completely. Sometimes it does not. The leg weakness you had the first time — did it recover 100%?

Valentina hesitates.

Valentina: — Casi. El 90%, tal vez. Todavía siento la pierna un poco diferente cuando camino mucho tiempo.

Almost. 90%, perhaps. I still feel the leg a little different when I walk for a long time.

Cristina: — Ese 10% que no volvió es el daño que quedó de la primera lesión. Si hay un segundo brote — especialmente sin la protección del medicamento — puede dejar otro 10%, o más. La EM no hace borrón y cuenta nueva entre brotes. Cada lesión acumula. Lo que queremos hacer es regresar al medicamento lo antes posible para que su sistema inmune vuelva a tener ese freno. ¿Hay algo que haya dificultado las inyecciones — las reacciones en el sitio de inyección, los síntomas al día siguiente?

That 10% that did not come back is the damage that remained from the first lesion. If there is a second relapse — especially without the protection of the medication — it can leave another 10%, or more. MS does not start fresh between relapses. Each lesion accumulates. What we want to do is return to the medication as soon as possible so your immune system has that brake again. Was there anything that made the injections difficult — the injection site reactions, the symptoms the next day?

Valentina: — Los primeros meses sí. Después ya casi no. No fue eso lo que me hizo pararlo — fue que me sentía tan bien que no le veía el punto.

The first months yes. Afterwards almost not. That was not what made me stop it — it was that I felt so well I did not see the point.

Cristina: — Y ahora usted sabe cuál es el punto — que esa sensación de estar bien no es la EM desaparecida. Es la EM quieta porque el medicamento no la dejaba actuar. ¿Podemos hablar hoy de cómo retomarlo?

And now you know what the point is — that feeling of being well is not the MS having disappeared. It is the MS quiet because the medication was not letting it act. Can we talk today about how to resume it?

Valentina: — Sí. Sí quiero reanudarlo.

Yes. I do want to resume it.

Scenario two: Eduardo and the three lesions he never felt

Eduardo Sánchez is 44. He is a restaurant manager from Houston. Fourteen months ago he woke up one morning with blurred vision in his left eye — like looking through frosted glass. By the end of the day he had lost roughly half of his visual field in that eye, accompanied by pain with eye movement. He went to the emergency department. He was told he had optic neuritis. He was given IV steroids. Over the next six weeks the vision returned almost completely — he has about 5% loss in color perception in that eye now, which he rarely notices.

He was referred to the MS clinic for evaluation. MRI at the time of the optic neuritis showed one lesion in the periventricular white matter — not enough lesions to meet the full diagnosis criteria. His neurologist discussed starting a first-line DMT. Eduardo decided to wait and monitor. He felt the optic neuritis had been a one-time event. His vision came back. He did not feel like someone who had MS.

The neurologist ordered a follow-up MRI at twelve months. The result arrived three weeks ago.

MS clinic nurse Patricia Vega is the one who called him to review the MRI findings and discuss the next appointment.

Eduardo: — La enfermera me dijo por teléfono que había tres lesiones nuevas. Pero yo me he sentido perfecto. No he tenido ningún problema de visión. No he tenido nada. Si el medicamento es para los brotes, ¿para qué sirve si yo no tuve un brote?

The nurse told me on the phone there are three new lesions. But I have felt perfect. I have not had any visual problems. I have not had anything. If the medication is for relapses, what is the point if I did not have a relapse?

Why the MRI shows activity that the patient never felt

Patricia: — Es exactamente la pregunta que hay que responder antes de hablar de cualquier tratamiento, y me alegra que la haga. El nervio óptico — donde ocurrió la neuritis óptica — es una de las pocas partes del sistema nervioso donde una lesión de EM produce síntomas que usted puede notar en tiempo real, porque cada fibra de ese nervio conecta directamente con lo que usted ve. La mayoría de las lesiones de EM no están en el nervio óptico. Están en áreas del cerebro — la sustancia blanca periventricular, el cuerpo calloso, el cerebelo, la médula espinal — donde el daño puede ocurrir en zonas que no controlan ninguna función que usted pueda percibir en este momento.

That is exactly the question that needs to be answered before talking about any treatment, and I am glad you asked it. The optic nerve — where the optic neuritis occurred — is one of the few parts of the nervous system where an MS lesion produces symptoms you can notice in real time, because every fiber of that nerve connects directly to what you see. Most MS lesions are not in the optic nerve. They are in areas of the brain — periventricular white matter, corpus callosum, cerebellum, spinal cord — where damage can occur in zones that do not control any function you can perceive at this moment.

Eduardo: — ¿Pero si no producen síntomas, por qué importan?

But if they do not produce symptoms, why do they matter?

Patricia: — Porque el daño de la lesión sí ocurrió, aunque usted no lo sintiera. Cuando la EM ataca la mielina en una zona del cerebro, el daño es real — el axón pierde su cubierta protectora en esa área. El axón puede sobrevivir por un tiempo así. Pero con el tiempo, y con lesiones que se acumulan, los axones desnudos se pueden dañar de manera permanente. La discapacidad en la EM a largo plazo no viene solo de los brotes que se sienten — viene de la acumulación de lesiones a lo largo de años, muchas de ellas silenciosas. Las tres lesiones que aparecieron en su resonancia son tres nuevas áreas de daño que su sistema inmune produjo en los últimos doce meses — sin que usted lo supiera y sin que produjera síntomas que pudiera notar.

Because the damage from the lesion did occur, even if you did not feel it. When MS attacks the myelin in an area of the brain, the damage is real — the axon loses its protective covering in that area. The axon can survive for a while that way. But over time, and with lesions that accumulate, the unprotected axons can become permanently damaged. Long-term disability in MS does not come only from the relapses you feel — it comes from the accumulation of lesions over years, many of them silent. The three lesions that appeared on your MRI are three new areas of damage your immune system produced in the past twelve months — without you knowing and without producing symptoms you could notice.

Eduardo is quiet for a moment.

Eduardo: — ¿Y si hubiera tomado el medicamento hace un año cuando me lo ofrecieron?

And if I had taken the medication a year ago when it was offered?

Patricia: — Los medicamentos de primera línea para la EM reducen la aparición de nuevas lesiones en la resonancia — no las eliminan todas, pero las reducen de manera significativa. No puedo decirle con certeza cuántas habría tenido con el medicamento — puede que ninguna, puede que una. Lo que sí podemos decir es que la decisión de ahora es distinta a la de hace un año, porque ahora tenemos la resonancia que muestra que la EM ha estado activa en ese tiempo. Eso es información que cambia la conversación sobre cuánta protección necesita su sistema nervioso.

The first-line medications for MS reduce the appearance of new lesions on MRI — they do not eliminate all of them, but they reduce them significantly. I cannot tell you with certainty how many you would have had with the medication — it might have been none, it might have been one. What we can say is that the decision today is different from the one a year ago, because now we have the MRI showing that MS has been active during that time. That is information that changes the conversation about how much protection your nervous system needs.

Why the neurologist is recommending a higher-efficacy treatment

Eduardo: — El neurólogo me dijo que quiere cambiar a un medicamento más fuerte. No entiendo por qué no empieza con el mismo que le dieron a otras personas que conozco con EM — el interferón, o el acetato de glatiramer. ¿Por qué directamente uno más fuerte?

The neurologist told me he wants to start with a stronger medication. I do not understand why he does not start with the same one given to other people I know with MS — interferon, or glatiramer acetate. Why go directly to a stronger one?

Patricia: — Hay dos formas de manejar la EM: una es empezar con un medicamento de eficacia moderada y escalarlo si hay actividad. La otra es empezar directamente con un medicamento de alta eficacia en pacientes que muestran señales de que la enfermedad va a ser más activa. Lo que su neurológo está usando para tomar esa decisión es la combinación de dos cosas: que usted tuvo neuritis óptica — que es un síntoma visible y significativo como primer evento — y que en doce meses sin tratamiento aparecieron tres lesiones nuevas. Eso es actividad de enfermedad que, en la literatura de EM, se asocia con un riesgo más alto de acumulación de discapacidad si no se controla. El razonamiento no es que su EM es muy severa hoy — es que los datos disponibles sugieren que necesita protección más agresiva ahora para evitar que sea severa en cinco o diez años.

There are two approaches to managing MS: one is to start with a moderate-efficacy medication and escalate if there is activity. The other is to start directly with a high-efficacy medication in patients who show signs that the disease will be more active. What your neurologist is using to make that decision is the combination of two things: that you had optic neuritis — which is a visible and significant symptom as a first event — and that in twelve months without treatment three new lesions appeared. That is disease activity that, in the MS literature, is associated with a higher risk of disability accumulation if not controlled. The reasoning is not that your MS is very severe today — it is that the available data suggest you need more aggressive protection now to prevent it from being severe in five or ten years.

Eduardo: — Entonces las tres lesiones que no sentí son la razón de que necesito el medicamento más fuerte.

So the three lesions I did not feel are the reason I need the stronger medication.

Patricia: — Exactamente. La resonancia no mide cómo se siente usted — mide lo que está pasando en el tejido nervioso, lo que usted sienta o no. Las tres lesiones silenciosas son la señal de que la EM estaba activa durante el año en que decidió esperar. No es un juicio sobre esa decisión — fue una decisión razonable con la información que tenía. Es la información nueva que tenemos ahora. ¿Quiere que le explique qué medicamento está proponiendo el neurólogo y cómo funciona?

Exactly. The MRI does not measure how you feel — it measures what is happening in the nerve tissue, whether you feel it or not. The three silent lesions are the signal that MS was active during the year you decided to wait. That is not a judgment about that decision — it was a reasonable decision with the information you had. It is the new information we now have. Would you like me to explain what medication the neurologist is proposing and how it works?

Eduardo: — Sí. Cuénteme.

Yes. Tell me.

Scenario three: María Luisa and the medication she saw advertised but was told she cannot have

María Luisa Reyes is 61. She is a retired seamstress from San Antonio. She spent forty years doing bridal alterations and formal wear — work that required sustained fine motor precision and close visual attention. Eight months ago her gait began to change. She noticed it first going up stairs: her left leg was not clearing the step reliably. By the time she got to her primary care physician, she was also experiencing urinary urgency and fatigue that she had attributed to aging. The MRI showed extensive cervical cord lesions without clear gadolinium enhancement, and the pattern was consistent with primary progressive multiple sclerosis.

Her neurologist confirmed the diagnosis. She was referred to the MS clinic. In the months since, María Luisa has been doing what people do after a new diagnosis — reading, watching, asking questions. She has seen television commercials. She has seen online advertisements. The medications she has seen described — some of them with the language of “changing the course of MS” — are drugs she now knows by name: natalizumab, ocrelizumab, siponimod.

At her last neurology appointment she asked directly: can she have those medications? Her neurologist said she was not a candidate for natalizumab. She was told ocrelizumab was a possibility, but the conversation was brief and she left without understanding what that meant.

MS clinic nurse Elena Vargas is meeting with María Luisa today for a nurse education visit.

María Luisa: — Veo todos esos anuncios de medicamentos para la esclerosis múltiple. Dicen que pueden cambiar el curso de la enfermedad. Mi doctor me dijo que yo no soy candidata. ¿Eso significa que mi esclerosis está muy avanzada para ayudarme? ¿O es que no me los dan porque tengo 61 años?

I see all those advertisements for multiple sclerosis medications. They say they can change the course of the disease. My doctor told me I am not a candidate. Does that mean my MS is too advanced to help? Or is it that they are not giving them to me because I am 61?

Elena: — No es ninguna de las dos cosas. Lo que le voy a explicar hoy es por qué los medicamentos que ve en los anuncios no son los mismos que se usan para el tipo de esclerosis múltiple que usted tiene — no porque el suyo sea más grave o porque tenga 61 años, sino porque son enfermedades diferentes a nivel biológico y los medicamentos están diseñados para mecanismos específicos. Esto es algo que el sistema médico no explica bien, y tiene razón en preguntar.

It is neither of those things. What I am going to explain today is why the medications you see in the advertisements are not the same ones used for the type of multiple sclerosis you have — not because yours is more severe or because you are 61, but because they are different diseases at the biological level and the medications are designed for specific mechanisms. This is something the medical system does not explain well, and you are right to ask.

The difference between relapsing-remitting and primary progressive MS

Elena: — La esclerosis múltiple tiene varios tipos. El más común — el que aparece en la mayoría de los anuncios — es el tipo recidivante-remitente. “Recidivante” significa que ocurren brotes: el sistema inmune lanza un ataque inflamatorio contra la mielina, produce síntomas durante semanas, y después la inflamación se calma. El síntoma puede mejorar parcialmente o completamente. El tipo que usted tiene — la EM primaria progresiva — no funciona así. No hay brotes seguidos de mejoría. Desde el principio, la función neurológica disminuye de manera gradual y continua. Las piernas — que es donde usted lo notó primero — van perdiendo función poco a poco, no de un brote a otro.

Multiple sclerosis has several types. The most common — the one that appears in most advertisements — is relapsing-remitting type. “Relapsing” means that relapses occur: the immune system launches an inflammatory attack against the myelin, produces symptoms for weeks, and then the inflammation quiets down. The symptom may improve partially or completely. The type you have — primary progressive MS — does not work that way. There are no relapses followed by improvement. From the beginning, neurological function decreases gradually and continuously. The legs — where you first noticed it — gradually lose function, not from one relapse to the next.

María Luisa: — ¿Y por qué eso hace que no pueda tomar los mismos medicamentos?

And why does that mean I cannot take the same medications?

Elena: — Porque la mayoría de los medicamentos que hay para la EM — los que ve en los anuncios: el natalizumab, el siponimod, el interferón — funcionan suprimiendo o modulando la respuesta inflamatoria que causa los brotes. Reducen la frecuencia de los ataques del sistema inmune a la mielina. Pero en la EM primaria progresiva, el problema principal no es ese ataque inflamatorio agudo. Es un proceso diferente: la degeneración progresiva de los axones y la pérdida de células nerviosas que ocurre independientemente de los brotes. Esos medicamentos no están diseñados para ese proceso, y cuando se estudiaron en ensayos clínicos en pacientes con EM primaria progresiva, no mostraron beneficio significativo — porque estaban atacando el mecanismo equivocado.

Because the majority of medications that exist for MS — the ones you see in advertisements: natalizumab, siponimod, interferon — work by suppressing or modulating the inflammatory response that causes relapses. They reduce the frequency of immune system attacks on myelin. But in primary progressive MS, the main problem is not that acute inflammatory attack. It is a different process: the progressive degeneration of axons and the loss of nerve cells that occurs independently of relapses. Those medications are not designed for that process, and when they were studied in clinical trials in patients with primary progressive MS, they did not show significant benefit — because they were attacking the wrong mechanism.

María Luisa: — ¿Entonces no hay nada para mí?

So there is nothing for me?

What exists for primary progressive MS

Elena: — Sí hay. En 2017, la FDA aprobó el ocrelizumab — que es el Ocrevus — específicamente para la EM primaria progresiva. Es el único medicamento aprobado para su tipo de esclerosis. Lo que lo hace diferente de los otros medicamentos es que no actúa principalmente sobre el mecanismo de los brotes. Actúa sobre las células B — un componente del sistema inmune que parece tener un papel en la degeneración progresiva de los axones que caracteriza la EM primaria progresiva. En los ensayos clínicos, el ocrelizumab mostró una disminución en la velocidad de progresión de la discapacidad en pacientes con EM primaria progresiva — comparado con placebo, los pacientes que tomaron ocrelizumab progresaron más lentamente.

Yes, there is. In 2017, the FDA approved ocrelizumab — which is Ocrevus — specifically for primary progressive MS. It is the only medication approved for your type of MS. What makes it different from the other medications is that it does not act primarily on the relapse mechanism. It acts on B cells — a component of the immune system that appears to have a role in the progressive axon degeneration that characterizes primary progressive MS. In clinical trials, ocrelizumab showed a decrease in the speed of disability progression in patients with primary progressive MS — compared to placebo, patients who took ocrelizumab progressed more slowly.

María Luisa: — ¿Más lentamente? ¿No lo para?

More slowly? Does it not stop it?

Elena: — No lo para. Y es importante que entienda eso con claridad, porque los anuncios a veces usan lenguaje que no lo dice directamente. Lo que el ocrelizumab puede hacer — según los datos de los ensayos — es desacelerar la velocidad a la que la esclerosis progresiva avanza. En el ensayo principal, la reducción fue de aproximadamente un 24% en el riesgo de progresión confirmada a doce semanas, comparado con placebo. Eso no significa que la mitad de los pacientes mejoraron — significa que la curva de deterioro fue más lenta en el grupo que tomó el medicamento. Para algunas personas eso es mucho. Para otras, la diferencia puede no ser tan perceptible en su experiencia diaria. Lo que sí sabemos es que es el único tratamiento aprobado que tiene efecto en el curso de la EM primaria progresiva.

It does not stop it. And it is important that you understand that clearly, because advertisements sometimes use language that does not say it directly. What ocrelizumab can do — according to trial data — is slow the rate at which the progressive MS advances. In the main trial, the reduction was approximately 24% in the risk of confirmed progression at twelve weeks, compared to placebo. That does not mean half of patients improved — it means the deterioration curve was slower in the group that took the medication. For some people that is significant. For others, the difference may not be as perceptible in their daily experience. What we do know is that it is the only approved treatment that has an effect on the course of primary progressive MS.

María Luisa: — ¿Y por qué el neurólogo me dijo que “puede ser una opción” pero no me lo recetó?

And why did the neurologist tell me it “may be an option” but did not prescribe it?

Elena: — La aprobación de la FDA para el ocrelizumab en EM primaria progresiva incluye criterios: pacientes con enfermedad activa definida por resonancia — ya sea lesiones con gadolinio que muestren inflamación activa, o lesiones nuevas en T2 comparadas con una resonancia anterior. Los ensayos mostraron beneficio principalmente en pacientes con algún componente inflamatorio todavía presente, no en pacientes en una fase puramente degenerativa sin actividad de imagen. Lo que su neurológo probablemente quería verificar antes de prescribirlo es si su resonancia muestra ese componente activo. ¿Tiene usted programada una resonancia con contraste próximamente?

The FDA approval for ocrelizumab in primary progressive MS includes criteria: patients with active disease defined by MRI — either gadolinium-enhancing lesions showing active inflammation, or new T2 lesions compared to a prior MRI. The trials showed benefit primarily in patients with some inflammatory component still present, not in patients in a purely degenerative phase without imaging activity. What your neurologist probably wanted to verify before prescribing it is whether your MRI shows that active component. Do you have a contrast MRI scheduled soon?

María Luisa: — La semana que viene.

Next week.

Elena: — Entonces la respuesta a su pregunta de si hay algo para usted es: sí hay. El ocrelizumab es el medicamento aprobado para la EM primaria progresiva. Su neurológo no se lo ha prescrito todavía porque quiere ver la resonancia primero para determinar si usted cumple los criterios de actividad que se asocian con mayor probabilidad de respuesta. No es que no haya opciones — es que el próximo paso es la resonancia, y esa información va a determinar la conversación del tratamiento. No tiene 61 años como razón para no tratar. No tiene la EM “demasiado avanzada.” Tiene un tipo de EM que necesita un tratamiento diferente, y ese tratamiento existe.

Then the answer to your question of whether there is something for you is: yes there is. Ocrelizumab is the approved medication for primary progressive MS. Your neurologist has not prescribed it yet because he wants to see the MRI first to determine whether you meet the activity criteria associated with greater probability of response. It is not that there are no options — it is that the next step is the MRI, and that information will determine the treatment conversation. You do not have 61 years as a reason for not treating. You do not have MS “too advanced.” You have a type of MS that needs a different treatment, and that treatment exists.

María Luisa looks at Elena for a long moment.

María Luisa: — Nadie me lo había explicado así. Yo pensé que me estaban dejando sin opciones.

No one had explained it to me like that. I thought they were leaving me without options.

Elena: — Tiene opciones. No son las mismas que aparecen en los anuncios para la EM recidivante, porque el proceso de su enfermedad es diferente. Pero existen, y vamos a hablar de ellas después de la resonancia de la semana que viene.

You have options. They are not the same ones that appear in the advertisements for relapsing MS, because the process of your disease is different. But they exist, and we are going to discuss them after next week’s MRI.

Eight practical phrases for multiple sclerosis clinic nurses

Each of the three conversations above involved a gap between what the patient understood and what she or he needed to understand in order to participate in their own treatment. Valentina had built a model in which feeling well was evidence that a medication had cured its target, and stopped a therapy that was working because its working looked like it was no longer necessary. Eduardo had focused on the relapse he could feel and the recovery he experienced, and could not see the disease activity that the MRI showed precisely because it had produced no symptoms he noticed. María Luisa had concluded from a conversation she did not fully understand that she was either beyond treatment or being denied it, and had begun to disengage from a clinic she believed could not help her. The phrases below give the MS clinic nurse the language to close each of those gaps in the time available at a scheduled visit or a nurse education call.

1. Explaining why feeling well does not mean MS is cured

The patient who stopped her medication because she felt fine needs the mechanism explained before any discussion of resuming can land.

El interferón no cura la EM. Lo que hace es suprimir el mecanismo con el que el sistema inmune ataca la mielina. Mientras el medicamento está en su cuerpo, el sistema inmune tiene un freno. Sentirse bien es la señal de que el freno estaba funcionando — no de que la EM se fue. Cuando se para el medicamento, el freno desaparece. La EM sigue estando ahí.

(Interferon does not cure MS. What it does is suppress the mechanism the immune system uses to attack myelin. While the medication is in your body, the immune system has a brake. Feeling well is the signal that the brake was working — not that the MS went away. When the medication is stopped, the brake disappears. The MS is still there.)

2. Explaining what stopping a DMT means for relapse risk

The patient who stopped her medication needs honest information about what the data show, without false certainty about whether or when a relapse will occur.

No podemos decirle con certeza si va a tener un brote ahora que paró el medicamento, ni cuándo. Lo que sí sabemos es que las personas que paran sus medicamentos de EM tienen más brotes en los meses siguientes que las que los continúan. El riesgo aumenta. Y cada brote puede dejar algo de daño que no siempre se recupera. Lo que queremos hacer es retomarlo lo antes posible.

(We cannot tell you with certainty whether you will have a relapse now that you stopped the medication, or when. What we do know is that people who stop their MS medications have more relapses in the following months than those who continue. The risk increases. And each relapse can leave some damage that does not always recover. What we want to do is resume it as soon as possible.)

3. Explaining why damage from prior relapses does not always fully recover

The patient who recovered “almost completely” from her first relapse needs to understand what the remaining deficit means for how subsequent relapses accumulate.

El 10% que no volvió después del primer brote es el daño que quedó de esa lesión. La EM no hace borrón y cuenta nueva entre brotes. Las lesiones se acumulan. Si hay un segundo brote, puede dejar otro 10% — o más. La función que se pierde en un brote no siempre vuelve. Por eso el objetivo del tratamiento no es solo evitar el próximo brote — es proteger la función que queda.

(The 10% that did not come back after the first relapse is the damage that remained from that lesion. MS does not start fresh between relapses. Lesions accumulate. If there is a second relapse, it can leave another 10% — or more. The function lost in a relapse does not always come back. That is why the goal of treatment is not only to prevent the next relapse — it is to protect the function that remains.)

4. Explaining what MRI shows that a clinical exam does not

The patient whose relapse resolved and who therefore concludes he is fine needs to understand the gap between subjective experience and imaging findings.

La resonancia mide la actividad de la EM en todo el tejido nervioso — no solo en las zonas que producen síntomas que usted puede sentir. Las lesiones que aparecieron en su resonancia están en áreas donde el daño no conecta con ninguna función que usted note ahora mismo. Pero el daño ocurrió. Se acumula. No sentirlo no significa que no estuviera pasando.

(The MRI measures MS activity across all nerve tissue — not only in the zones that produce symptoms you can feel. The lesions that appeared on your MRI are in areas where the damage does not connect to any function you notice right now. But the damage occurred. It accumulates. Not feeling it does not mean it was not happening.)

5. Explaining why a neurologist recommends escalating to a higher-efficacy DMT after silent lesions

The patient who had one visible relapse but shows new MRI activity needs to understand the reasoning behind an escalation that seems disproportionate to his symptoms.

Tres lesiones nuevas en doce meses sin tratamiento es actividad de enfermedad que, en la literatura de EM, se asocia con mayor riesgo de discapacidad acumulada si no se controla. El razonamiento no es que su EM es severa hoy — es que los datos sugieren que necesita más protección ahora para evitar que sea severa en diez años. Las resonancias son la información que permite tomar esa decisión con los datos del tejido nervioso, no solo con los síntomas que se pueden sentir.

(Three new lesions in twelve months without treatment is disease activity that, in the MS literature, is associated with higher risk of accumulated disability if not controlled. The reasoning is not that your MS is severe today — it is that the data suggest you need more protection now to prevent it from being severe in ten years. MRIs are the information that allows that decision to be made with nerve tissue data, not only with the symptoms that can be felt.)

6. Explaining the difference between relapsing-remitting and primary progressive MS

The patient with PPMS who cannot understand why she is not a candidate for the treatments she sees advertised needs the biological distinction explained, not the difference in approval status.

La EM recidivante-remitente tiene brotes: el sistema inmune lanza ataques inflamatorios que producen síntomas y después se calman. Los medicamentos de los anuncios están diseñados para frenar esos ataques. La EM primaria progresiva no tiene brotes — progresa gradualmente por un mecanismo diferente, no por el ataque inflamatorio agudo. Los medicamentos de los anuncios no están diseñados para ese mecanismo. No es que no pueda usarlos — es que no están hechos para lo que su enfermedad hace.

(Relapsing-remitting MS has relapses: the immune system launches inflammatory attacks that produce symptoms and then quiet down. The medications in the advertisements are designed to brake those attacks. Primary progressive MS does not have relapses — it progresses gradually through a different mechanism, not through the acute inflammatory attack. The medications in the advertisements are not designed for that mechanism. It is not that you cannot use them — it is that they are not made for what your disease does.)

7. Explaining what ocrelizumab offers for PPMS

The patient with PPMS who has never been told what treatment does exist for her type needs honest information about what ocrelizumab offers: slowing, not stopping.

El ocrelizumab es el único medicamento aprobado por la FDA para la EM primaria progresiva. Actúa sobre un componente diferente del sistema inmune — las células B — que parece tener un papel en la degeneración progresiva. En los ensayos clínicos mostró una desaceleración del avance de la discapacidad — no lo para, no lo revierte, pero lo hace más lento comparado con placebo. Para algunos pacientes esa diferencia es significativa. Es el único tratamiento aprobado que tiene efecto demostrado en el curso de la EM primaria progresiva.

(Ocrelizumab is the only FDA-approved medication for primary progressive MS. It acts on a different component of the immune system — B cells — that appears to have a role in progressive degeneration. In clinical trials it showed a slowing of disability advancement — it does not stop it, does not reverse it, but it makes it slower compared to placebo. For some patients that difference is significant. It is the only approved treatment with demonstrated effect on the course of primary progressive MS.)

8. Correcting the conclusion that no treatment means no options

The patient with PPMS who has concluded she is either too advanced or being excluded because of her age needs that conclusion corrected before she disengages from care.

No le falta tratamiento porque tiene 61 años. No le falta tratamiento porque su EM es demasiado avanzada. Tiene un tipo de EM que necesita un tratamiento diferente al de los anuncios, y ese tratamiento existe. El siguiente paso es verificar su resonancia para confirmar los criterios. La conversación sobre el ocrelizumab viene después de eso — no estamos esperando para dejarla sin opciones. Estamos esperando la información que hace que el medicamento correcto tenga la mejor probabilidad de funcionar.

(You are not without treatment because you are 61. You are not without treatment because your MS is too advanced. You have a type of MS that needs a different treatment from the ones in the advertisements, and that treatment exists. The next step is to verify your MRI to confirm the criteria. The conversation about ocrelizumab comes after that — we are not waiting to leave you without options. We are waiting for the information that gives the right medication the best probability of working.)

Practice these conversations with ClinicaLingo

The three conversations in this post involve a kind of clinical communication that does not appear in most Spanish-for-healthcare courses: explaining why a medication that makes a patient feel better is not a medication she can stop, why imaging findings that produced no symptoms are still clinically significant, and why the treatments a patient sees advertised for her diagnosis are not the treatments designed for the type of that diagnosis she has. These are not translation problems. They are explanatory problems — the clinician needs to explain a mechanism that is counterintuitive (feeling well as evidence of drug efficacy, not drug dispensability), a discrepancy that is invisible to the patient (MRI lesions with no symptoms), and a distinction that the advertising landscape actively obscures (RRMS versus PPMS in the same commercials). Getting that explanation right in Spanish — with the vocabulary that maps to what the patient has been reading online, with the metaphors that make the immune mechanism legible, with the tone that is honest about what treatment can and cannot do — takes practice. The ClinicaLingo practice scenarios cover MS clinic conversations alongside the other clinical specialties in this library. The 50-phrase PDF gives you the phrases that appear most often across the 154-scenario library, organized by clinical situation. The full blog library has posts covering every specialty from ED triage to NICU to correctional health nursing.